Physician profile
Ranvir Singh
NPI 1487312617
$293.48
in general payments reported to CMS, 2019-2025
9 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $67.38 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $66.13 | 2025 | Mycapssa |
| Lilly USA, LLC | $60.26 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Civco Medical Instruments | $24.40 | 2025 | |
| Boston Scientific Corporation | $24.37 | 2025 | General - Kidney Stone Disease |
| Janssen Biotech, INC. | $24.08 | 2024 | Erleada, Balversa, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $23.91 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $23.86 | 2024 | |
| Recordati_rare_diseases_inc. | $23.47 | 2025 | Isturisa |
| Novo Nordisk INC | $23.00 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranvir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.